EU Grant Fuels Novel Virus Therapy for Deadly Ovarian Cancer

OXFORD, UK – March 04, 2026 – Theolytics, an Oxford-based biotechnology firm, has secured a landmark €8 million grant from the European Union's flagship research program, Horizon Europe 2025. The highly competitive, non-dilutive funding is set to accelerate a pivotal Phase 2 study of THEO-260, a novel oncolytic virus therapy showing promise against one of the most challenging and lethal malignancies: platinum-resistant ovarian cancer. The award not only provides a critical financial runway but also serves as a major validation of the company's innovative approach to dismantling a tumor's defenses from the inside out.

A Beacon of Hope for a Devastating Disease

For women diagnosed with platinum-resistant ovarian cancer, the prognosis is often grim. The disease is defined by its recurrence and progression within just six months of completing standard platinum-based chemotherapy, the frontline treatment. This resistance leaves clinicians with limited, often poorly effective, options. The median survival for these patients is typically a mere 12 to 18 months, a stark statistic that underscores a desperate unmet medical need.

"We see many women with advanced platinum-resistant ovarian cancer, whose life expectancy is typically only a year or less," said Dr. Antonio González, Director of the Department of Medical Oncology and Cancer Center at the Clínica Universidad de Navarra, and President of the Spanish Cooperative Group for Gynaecological Cancer Research. "There remains a serious lack of effective treatment options for these women, and so we are hopeful that THEO-260 may bring an advance in therapy that will improve and extend the lives of our patients.”

The funding will support the OCTOPOD-IV trial, a Phase 2a expansion study that will enroll up to 20 patients, providing them access to this experimental therapy. The study is not just about measuring efficacy; it's about generating hope in a patient population that has been largely left behind by recent therapeutic breakthroughs.

Deconstructing the Fortress: A Novel 'CAF-lytic' Approach

At the heart of Theolytics' strategy is a sophisticated biological weapon: an oncolytic virus. These are viruses engineered to selectively hunt, infect, and destroy cancer cells—a process called oncolysis. But the true power of modern oncolytic immunotherapies lies in their secondary effect: by causing a chaotic death of cancer cells, they release a flood of tumor-specific antigens, effectively ringing an alarm bell that awakens the patient's own immune system to join the fight.

However, advanced tumors, particularly in ovarian cancer, have built formidable defenses. A key component of this defense is a dense, fibrous wall of tissue known as stroma, which is largely constructed by cells called cancer-associated fibroblasts (CAFs). These CAFs not only form a physical barrier that blocks immune cells and drugs from reaching the tumor but also secrete signals that actively suppress the immune system.

This is where THEO-260's innovation shines. It is designed with a unique dual-action mechanism. Beyond killing cancer cells, it has a 'CAF-lytic' capability, meaning it is also engineered to specifically target and destroy the CAFs.

"Our collective success with this grant award reflects the extraordinary work being done by the team at Theolytics, and the calibre of our clinical and translational partner centres," stated Margaret Duffy, CSO and Co-founder of Theolytics. "The Horizon Europe award validates both the scientific rationale behind our THEO-260 programme and the huge potential of its novel oncolytic and ‘CAF-lytic’ mechanism to address a significant unmet need in stroma-rich solid cancers. By integrating advanced translational analyses into our clinical trial design, we will clinically demonstrate the differentiated mechanism of action of THEO-260 and provide key data to advance this programme and deliver true impact for cancer patients.”

By dismantling the tumor's protective stromal fortress, THEO-260 aims to achieve a one-two punch: directly killing tumor cells and their support structure, while simultaneously tearing down the walls that hide the cancer from the body's immune defenses.

The European Stamp of Approval

The €8 million grant is more than just financial fuel; it is a prestigious endorsement from one of the world's most rigorous scientific funding bodies. The Horizon Europe program, with a budget of €95.5 billion, is designed to foster innovation and strengthen Europe’s scientific and technological leadership. The specific call under which Theolytics succeeded—"Boosting the translation of biotech research into innovative health therapies"—is notoriously competitive, with success rates sometimes dipping into the single digits.

Securing this award required passing a stringent review of the project's scientific excellence, potential impact, and the quality of the implementation plan. It signifies that a panel of independent experts believes THEO-260 has a credible chance of transforming patient outcomes. The funding structure, which supports Small and Medium-sized Enterprises (SMEs), also reflects the EU's strategy to empower agile, innovative companies like Theolytics to become leaders in the global health biotech sector, bridging the perilous "valley of death" between early research and late-stage clinical development.

Two-thirds of the funds will go directly to Theolytics to run the clinical trial, while the remaining third will be deployed to its world-class partners, ensuring the entire collaborative effort is well-resourced.

A Global Alliance for a Global Problem

The fight against cancer is a global effort, and Theolytics has assembled an international consortium of some of the world's top cancer research institutions. The grant application and the OCTOPOD-IV trial were coordinated with the University of Navarra and the Catalan Institute of Oncology in Spain, the Princess Margaret Cancer Centre in Toronto, and The Institute of Cancer Research (ICR) in London.

"The differentiated mechanism of action – targeting the stroma and inducing immune activity in the suppressed tumour microenvironment (TME) - of this oncolytic immunotherapy THEO-260 offers the potential to provide an important new treatment option for patients with advanced solid tumours," commented Prof Alan Melcher, Professor of Translational Immunotherapy at The Institute of Cancer Research, London. "We are pleased to support the OCTOPOD-IV study, for which the ICR will provide important translational data to assess this novel and promising approach."

The company's clinical strategy extends beyond this single trial. Recruitment for OCTOPOD-IV is already underway in the UK and Spain and will now expand to Canada. Furthermore, a second, parallel trial named OCTOPOD-IP has been initiated in the United States in collaboration with the renowned MD Anderson Cancer Center in Texas. This second study will investigate a different route of administration—intraperitoneal delivery—directly into the abdominal cavity where ovarian cancer often spreads, exploring another potential avenue to maximize the therapy's impact.

This multi-pronged, international clinical program, now significantly bolstered by European funding, represents a coordinated and powerful assault on a disease that has defied researchers for decades. With its innovative science and a global network of experts, Theolytics is poised to find out if its engineered virus can deliver a meaningful breakthrough for patients who have run out of time and options.